Literature DB >> 17509853

Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.

Harold R Collard1, James E Loyd, Talmadge E King, Lisa H Lancaster.   

Abstract

Little is known about practice patterns regarding the diagnosis and management of idiopathic pulmonary fibrosis (IPF). This study attempts to define the practice patterns of academic pulmonologists caring for patients with IPF. Academic pulmonologists in the United States were surveyed electronically. Completed surveys were received from 272 respondents (representing approximately 10% of academic pulmonologists). The majority agreed that high-resolution computed tomography can establish the diagnosis of IPF, and that surgical lung biopsy is indicated when the diagnosis remains unclear. Bronchoscopy is little utilized. Most respondents treat patients with medications, but there is no consensus regarding treatment regimen. These results suggest there is general consensus regarding the approach to diagnosis, but that there is no consensus about medical management in IPF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17509853      PMCID: PMC2042103          DOI: 10.1016/j.rmed.2007.03.012

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  22 in total

1.  Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis.

Authors:  G W Hunninghake; M B Zimmerman; D A Schwartz; T E King; J Lynch; R Hegele; J Waldron; T Colby; N Müller; D Lynch; J Galvin; B Gross; J Hogg; G Toews; R Helmers; J A Cooper; R Baughman; C Strange; M Millard
Journal:  Am J Respir Crit Care Med       Date:  2001-07-15       Impact factor: 21.405

2.  Incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster
Journal:  Am J Respir Crit Care Med       Date:  2006-06-29       Impact factor: 21.405

3.  Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival.

Authors:  K R Flaherty; G B Toews; J P Lynch; E A Kazerooni; B H Gross; R L Strawderman; K Hariharan; A Flint; F J Martinez
Journal:  Am J Med       Date:  2001-03       Impact factor: 4.965

4.  The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study.

Authors:  G Raghu; Y N Mageto; D Lockhart; R A Schmidt; D E Wood; J D Godwin
Journal:  Chest       Date:  1999-11       Impact factor: 9.410

5.  The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis.

Authors:  A G Nicholson; T V Colby; R M du Bois; D M Hansell; A U Wells
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

6.  Clinical significance of histological classification of idiopathic interstitial pneumonia.

Authors:  K R Flaherty; G B Toews; W D Travis; T V Colby; E A Kazerooni; B H Gross; A Jain; R L Strawderman; R Paine; A Flint; J P Lynch; F J Martinez
Journal:  Eur Respir J       Date:  2002-02       Impact factor: 16.671

Review 7.  Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.

Authors:  M Selman; T E King; A Pardo
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

8.  Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival.

Authors:  W W Douglas; J H Ryu; D R Schroeder
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

9.  Radiological versus histological diagnosis in UIP and NSIP: survival implications.

Authors:  K R Flaherty; E L Thwaite; E A Kazerooni; B H Gross; G B Toews; T V Colby; W D Travis; J A Mumford; S Murray; A Flint; J P Lynch; F J Martinez
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

10.  A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Kevin K Brown; Williamson Z Bradford; Karen Starko; Paul W Noble; David A Schwartz; Talmadge E King
Journal:  N Engl J Med       Date:  2004-01-08       Impact factor: 91.245

View more
  12 in total

1.  Effect of treatment guidelines on the initial management of idiopathic pulmonary fibrosis.

Authors:  Jeffrey C Munson; Maryl Kreider; Zhen Chen; Jason D Christie; Stephen E Kimmel
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

2.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Proposal.

Authors:  Kerri Johannson; Harold R Collard
Journal:  Curr Respir Care Rep       Date:  2013-12

3.  Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis.

Authors:  Adam Fang; Sean Studer; Steven M Kawut; Vivek N Ahya; James Lee; Keith Wille; Vibha Lama; Lorraine Ware; Jonathan Orens; Ann Weinacker; Scott M Palmer; Maria Crespo; David J Lederer; Clifford S Deutschman; Benjamin A Kohl; Scarlett Bellamy; Ejigayehu Demissie; Jason D Christie
Journal:  Chest       Date:  2010-09-23       Impact factor: 9.410

4.  Factors associated with the use of corticosteroids in the initial management of idiopathic pulmonary fibrosis.

Authors:  Jeffrey C Munson; Maryl Kreider; Zhen Chen; Jason D Christie; Stephen E Kimmel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-07       Impact factor: 2.890

5.  Mycophenolate in scleroderma-associated interstitial lung disease: Real-world data from rheumatology and pulmonology clinics in South Asia.

Authors:  Ramya Janardana; Aparna Irodi; Pramod P Chebbi; Ruchika Goel; Leena R Vimala; Shivraj Padiyar; Anoof Peediyakal; John Mathew; Aswin Nair; Devasahayam J Christopher; Debashish Danda
Journal:  J Scleroderma Relat Disord       Date:  2021-06-30

6.  Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis.

Authors:  Jared T Hagaman; Brent W Kinder; Mark H Eckman
Journal:  Lung       Date:  2010-04       Impact factor: 2.584

7.  Efficacy of concurrent treatments in idiopathic pulmonary fibrosis patients with a rapid progression of respiratory failure: an analysis of a national administrative database in Japan.

Authors:  Keishi Oda; Kazuhiro Yatera; Yoshihisa Fujino; Hiroshi Ishimoto; Hiroyuki Nakao; Tetsuya Hanaka; Takaaki Ogoshi; Takashi Kido; Kiyohide Fushimi; Shinya Matsuda; Hiroshi Mukae
Journal:  BMC Pulm Med       Date:  2016-06-08       Impact factor: 3.317

8.  Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey.

Authors:  Vincent Cottin; Emmanuel Bergot; Arnaud Bourdin; Jacques Cadranel; Philippe Camus; Bruno Crestani; Jean-Charles Dalphin; Philippe Delaval; Claire Dromer; Dominique Israel-Biet; Romain Kessler; Sylvain Marchand-Adam; Charles Hugo Marquette; Grégoire Prévot; Martine Reynaud-Gaubert; Dominique Valeyre; Benoit Wallaert; Benoit Bouquillon; Jean-François Cordier
Journal:  ERJ Open Res       Date:  2015-11-16

9.  Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.

Authors:  Padmanabha D Shenoy; Manish Bavaliya; Sujith Sashidharan; Kaveri Nalianda; Sreelakshmi Sreenath
Journal:  Arthritis Res Ther       Date:  2016-06-02       Impact factor: 5.156

10.  Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique.

Authors:  Toby M Maher; Moira K B Whyte; Rachel K Hoyles; Helen Parfrey; Yuuki Ochiai; Nicky Mathieson; Alice Turnbull; Nicola Williamson; Bryan M Bennett
Journal:  Adv Ther       Date:  2015-10-23       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.